GSK voluntarily halts production on 2 varieties of Excedrin
GlaxoSmithKline is temporarily pausing production on two varieties of its migraine medication Excedrin, according to multiple news reports. The company told ABC News that nationwide production and distribution of Excedrin Migraine and Excedrin Extra strength due to “inconsistencies in how we transfer and weigh ingredients.”
A GSK spokesperson told Drug Store News, "GSK Consumer Healthcare is experiencing a temporary supply issue that impacts on the following products: Excedrin Extra Strength Caplets and Geltabs and Excedrin Migraine Caplets and Geltabs. We apologize for any inconvenience this stock issue may cause to consumers. Please be assured we are working hard to resolve the issue so we can restore supply as quickly as possible."